Evidence map›Paper›PMID 20818421›Full record

ArticleOncogene2011

Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness.

X Li, M Martinez-Ferrer, V Botta, C Uwamariya, J Banerjee, N A Bhowmick

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Physiological and pathological roles of Hic‑5 in several organs (Review).International journal of molecular medicine · 2022
    Review
  2. Article
  3. Review
  4. SOX4: The unappreciated oncogene.Seminars in cancer biology · 2020
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Wnt signaling in castration-resistant prostate cancer: implications for therapy.American journal of clinical and experimental urology · 2014
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

X LiThe Vanderbilt-Ingram Cancer Center and Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA.
M Martinez-Ferrer
V Botta
C Uwamariya
J Banerjee
N A Bhowmick
Vanderbilt University · USCedars-Sinai Medical Center · US

Funding

Protein Collection and Proteomics Integrative Shared ResourceU54CA126505 · NCI · VANDERBILT UNIVERSITY · PI MATRISIAN, LYNN M · 2006 to 2010
$8.2M
TGFB Signals in Prostate Stromal-Epithelial InteractionsR01CA108646 · NCI · VANDERBILT UNIVERSITY · PI BHOWMICK, NEIL A. · 2004 to 2016
$2.9M
NCI NIH HHS CA108646NCI NIH HHS CA126505NCI NIH HHS R01 CA108646NCI NIH HHS U54 CA126505
6 · The paper itself

Abstract

Stromal-epithelial interactions dictate prostate tumorigenesis and response to castration. Hydrogen peroxide-inducible clone 5 (Hic-5/ARA55) is a transforming growth factor-beta (TGF-β)-induced coactivator of androgen receptor (AR) expressed in the prostate stroma. Interestingly, following castration, we identified epithelial expression of Hic-5/ARA55 in mouse and human prostate tissues. To determine the role of epithelial Hic-5 in prostate cancer progression and castration responsiveness, we compared LNCaP cells having Hic-5 stably expressed with the parental LNCaP cells following tissue recombination xenografts with mouse prostate stromal cells. We previously identified knocking out prostate stromal TGF-β signaling potentiated castrate-resistant prostate tumors, in a Wnt-dependent manner. The LNCaP chimeric tumors containing prostate fibroblasts conditionally knocked out for the TGF-β type II receptor (Tgfbr2-KO) resulted in larger, more invasive, and castration-resistant tumors compared those with floxed (control) stromal cells. However, the LNCaP-Hic5 associated with Tgfbr2-KO fibroblasts generated chimeric tumors with reduced tumor volume, lack of invasion and restored castration dependence. Neutralization of canonical Wnt signaling is shown to reduce prostate tumor size and restore regression following castration. Thus, we hypothesized that epithelial Hic-5/ARA55 expression negatively regulated Wnt signaling. The mechanism of the Hic-5/ARA55 effects on castration was determined by analysis of the c-myc promoter. C-myc luciferase reporter activity suggested Hic-5/ARA55 expression inhibited c-myc activity by β-catenin. Sequential ChIP analysis indicated β-catenin and T-cell-specific 4 (TCF4) bound the endogenous c-myc promoter in the absence of Hic-5 expression. However, the formation of a TCF4/Hic-5 repressor complex inhibited c-myc promoter activity, by excluding β-catenin binding with TCF4 on the promoter. The data indicate Hic-5/ARA55 expression in response to castration-enabled epithelial regression through the repression of c-myc gene at the chromatin level.

Indexed as

AnimalsBasic Helix-Loop-Helix Leucine Zipper Transcription Factorsbeta CateninCell Line, TumorCell Transformation, NeoplasticCytoskeletal ProteinsDNA-Binding ProteinsGenes, mycHumansIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsMaleMiceMice, Inbred C57BLMice, SCIDOrchiectomyBasic Helix-Loop-Helix Leucine Zipper Transcription Factorsbeta CateninCytoskeletal ProteinsDNA-Binding ProteinsIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsProtein Serine-Threonine KinasesReceptors, AndrogenReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IITCF4 protein, humanTGFB1I1 protein, humanTgfb1i1 protein, mouseTranscription Factor 4Transcription FactorsWnt Proteins

Identifiers

PMID20818421
PMCPMC3021901
OpenAlexW2063232779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.